SUMMARY

bimatoprost

IRICRYN 0.3 mg/mL

eye drops, solution

Inclusion on list: First listing

Hybrid

Adopted by the Transparency Committee on 20 November 2024

Summary of opinion

Favourable opinion for reimbursement in the treatment of chronic open-angle glaucoma or the treatment of ocular hypertension.

No clinical added value compared to the reference medicinal product already available (LUMIGAN 0.3 mg/mL, bimatoprost, eye drops, solution in single-dose containers).

Transparency Committee's conclusions

Clinical Benefit

- Chronic open-angle glaucoma and ocular hypertension are severe conditions that can cause blindness.
- IRICRYN (bimatoprost) 0.3 mg/mL eye drops solution, is a curative treatment for elevated intra-ocular pressure and a preventive treatment for complications of the condition.
- The efficacy/adverse effects ratio is high.
- This is a first or second-line treatment in view of the therapeutic alternatives available.

- **Public health benefit:**

IRICRYN (bimatoprost) is unlikely to have an additional impact on public health compared to the reference medicinal product, LUMIGAN (bimatoprost) 0.3 mg/mL eye drops, solution in single-dose containers.

The Committee considers that the clinical benefit of IRICRYN (bimatoprost) 0.3 mg/mL eye drops solution, is substantial in the MA indication.

The Committee issues a favourable opinion for inclusion in both the list of covered drugs for outpatients and the list of covered drugs for inpatients approved for use in the indication and at the MA dosages.

➔ **Recommended reimbursement rate for inclusion in the list of covered drugs for outpatients: 65%**

Clinical Added Value

This medicinal product is a hybrid that does not provide any clinical added value (CAV V) compared to the reference medicinal product.